The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -12.76%.However, over the last six months, we can see a stronger performance of -3.70%. Over the last 30 days, the price of EBS has leaped by -16.35%. And in the last five days, it has fallen by -17.51%.
Emergent Biosolutions Inc’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $15.10 on 07/30/24 and a low of $1.48 for the same time frame on 02/20/24.
52-week price history of EBS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Emergent Biosolutions Inc’s current trading price is -44.77% away from its 52-week high, while its distance from the 52-week low is 463.51%. The stock’s price range during this period has varied between$1.48 and $15.10. The Emergent Biosolutions Inc’s shares, which operate in the Healthcare, saw a trading volume of around 1.91 million for the day, a figure considerably higher than their average daily volume of 1.05 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Emergent Biosolutions Inc (EBS) has experienced a quarterly decline of -16.35% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 451.90M and boasts a workforce of 1600 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 9.41, with a change in price of +2.28. Similarly, Emergent Biosolutions Inc recorded 1,332,590 in trading volume during the last 100 days, posting a change of +37.62%.
EBS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for EBS stands at 1.33. Similarly, the long-term debt-to-equity ratio is also 1.32.
EBS Stock Stochastic Average
As of today, Emergent Biosolutions Inc’s raw stochastic average for the last 50 days stands at 14.95%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 0.27%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 14.26% and 15.94%, respectively.
